These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21248158)

  • 1. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Mei W; McNeil S; Money D; Dionne M; Karunakaran KP; Palefsky JM; Dobson S; Ogilvie G; Petric M
    Clin Vaccine Immunol; 2011 Mar; 18(3):418-23. PubMed ID: 21248158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
    Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
    Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
    Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination.
    Scherpenisse M; Schepp RM; Mollers M; Mooij SH; Meijer CJ; Berbers GA; van der Klis FR
    Clin Vaccine Immunol; 2013 Aug; 20(8):1329-32. PubMed ID: 23740920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
    Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT
    Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.
    Brown D; Müller M; Sehr P; Pawlita M; Seitz H; Rubio I; Antonello J; Radley D; Roberts C; Saah A
    Vaccine; 2014 Oct; 32(44):5880-7. PubMed ID: 25148777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
    Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV
    Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
    Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
    Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
    PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the HPV 18 antibody response in Gardasil® vaccinees after 48 mo using a pseudovirion neutralization assay.
    Roberts C; Swoyer R; Bryan J
    Hum Vaccin Immunother; 2012 Apr; 8(4):431-4. PubMed ID: 22336880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.
    Roberts C; Green T; Hess E; Matys K; Brown MJ; Haupt RM; Luxembourg A; Vuocolo S; Saah A; Antonello J
    Hum Vaccin Immunother; 2014; 10(8):2168-74. PubMed ID: 25424920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method.
    Toh ZQ; He L; Chen C; Huang A; Russell FM; Garland SM; Reyburn R; Ratu T; Tuivaga E; Frazer IH; Mulholland EK; Licciardi PV
    Front Immunol; 2020; 11():585768. PubMed ID: 33193410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.
    Hillman RJ; Giuliano AR; Palefsky JM; Goldstone S; Moreira ED; Vardas E; Aranda C; Jessen H; Ferris DG; Coutlee F; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI
    Clin Vaccine Immunol; 2012 Feb; 19(2):261-7. PubMed ID: 22155768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
    Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
    J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.
    Kemp TJ; Matsui K; Shelton G; Safaeian M; Pinto LA
    Hum Vaccin Immunother; 2015; 11(2):337-46. PubMed ID: 25695397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
    Wu T; Hu YM; Li J; Chu K; Huang SJ; Zhao H; Wang ZZ; Yang CL; Jiang HM; Wang YJ; Lin ZJ; Pan HR; Sheng W; Wei FX; Li SW; Wang Y; Zhu FC; Li CG; Zhang J; Xia NS
    Vaccine; 2015 Jul; 33(32):3940-6. PubMed ID: 26100924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
    Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
    Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
    J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.